Core Viewpoint - The article discusses the benefits of GLP-1 receptor agonists, such as semaglutide and tirzepatide, in weight loss without significant muscle mass loss, highlighting their positive impact on body composition and energy levels [4][6][10]. Group 1: Research Findings - A study published in JAMA indicates that patients using GLP-1 receptor agonists do not need to worry about excessive muscle loss during rapid weight loss [4]. - Semaglutide has been shown to increase the proportion of lean body mass relative to total weight, leading to higher muscle quality and potential energy expenditure at lower body weights [4][6]. - The relationship between fat-free mass (FFM) and skeletal muscle mass (SMM) ratios and overall weight loss is explored, suggesting that maintaining or slightly increasing muscle mass can enhance basal metabolic rate [6][7]. Group 2: Clinical Perspectives - Concerns regarding muscle loss from GLP-1 agonists are described as hypothetical, with no substantial evidence supporting these fears [9][10]. - Medical professionals report that patients generally do not express concerns about muscle loss, focusing instead on weight loss and overall health improvements [10]. - Recommendations for patients include engaging in strength training and increasing protein intake to preserve muscle mass during weight loss [10]. Group 3: Cautionary Notes - Caution is advised for elderly patients and those losing more than 25% of their body weight, as they may face risks related to muscle loss and bone density [11]. - Additional monitoring, such as body composition scans and blood tests, is suggested for patients experiencing significant weight loss to ensure safety and health [11].